EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Elexacaftor/tezacaftor/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis

Charlotte O Pioch, Niklas Ziegahn, Christine Allomba, Leonie M Busack, Alexandra N Schnorr, Apolline Tosolini, Bent R Fuhlrott, Styliani Zagkla, Till Othmer, Zulfiya Syunyaeva, Simon Y Graeber, Mehrak Yoosefi und 5 weitere

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2024.03.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Charlotte O Pioch und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Nitric Oxide, Indoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In health, nitric oxide (NO) shows high concentrations in the upper airways, while nasal NO (nNO) is significantly lower in patients with sinonasal inflammation, such as people with cystic fibrosis (PwCF). In PwCF treated with elexacaftor/tezacaftor/ivacaftor (ETI; PwCF-ETI), clinical improvement of sinonasal symptoms and inflammation was observed. We therefore hypothesised that ETI may increase nNO in PwCF. METHODS: 25 PwCF-ETI underwent nNO measurement at baseline and after 3 to 24 months of ETI treatment. NNO was measured using velum closure (VC) techniques in cooperative patients and tidal breathing (TB) for all patients. As controls, 7 CF patients not eligible for ETI (PwCF-non ETI) and 32 healthy controls (HC) were also repeatedly investigated. RESULTS: In PwCF-ETI, sinonasal symptoms, lung function parameters and sweat chloride levels improved from baseline to follow-up whereas there was no change in PwCF-non ETI and HC. NNO increased from a median (IQR) value at baseline to follow-up from 348.2 (274.4) ppb to 779.6 (364.7) ppb for VC (P < 0.001) and from 198.2 (107.0) ppb to 408.3 (236.1) ppb for TB (P < 0.001). At follow-up, PwCF-ETI reached nNO values in the normal range. In PwCF-non ETI as well as HC, nNO did not change between baseline and follow-up. CONCLUSIONS: In PwCF-ETI, the nNO values significantly increased after several months of ETI treatment in comparison to baseline and reached values in the normal range. This suggests that nNO is a potential non-invasive biomarker to examine sinonasal inflammatory disease in PwCF and supports the observation of clinical improvement in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBenzodioxolesNitric OxideIndolesAminophenolsQuinolonesDrug CombinationsPyrazolesHumansFemaleMaleAdultPyridinesPyrrolidinesAdolescentYoung AdultChloride Channel AgonistsRespiratory Function TestsTreatment OutcomeSinusitis

Stichwörter der Autor:innen

ChildrenNasal nitric oxideNon-invasive outcome measureSinonasal disease

Substanzen

BenzodioxolesNitric OxideIndolesAminophenolsQuinolonesDrug CombinationsPyrazolesPyridinesPyrrolidineselexacaftor

Autor:innen und Institutionen

  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany…

Förderung

  • Deutsche Forschungsgemeinschaft
  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Pioch, C. O., Ziegahn, N., Allomba, C., Busack, L. M., Schnorr, A. N., Tosolini, A., Fuhlrott, B. R., Zagkla, S., Othmer, T., Syunyaeva, Z., Graeber, S. Y., Yoosefi, M., Thee, S., Steinke, E., Röhmel, J., Mall, M. A., & Stahl, M. (2024). Elexacaftor/tezacaftor/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.03.003

Vancouver

Pioch CO, Ziegahn N, Allomba C, Busack LM, Schnorr AN, Tosolini A, et al. Elexacaftor/tezacaftor/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.03.003

BibTeX
@article{Pioch2024,
  author = {Pioch, Charlotte O and Ziegahn, Niklas and Allomba, Christine and Busack, Leonie M and Schnorr, Alexandra N and Tosolini, Apolline and Fuhlrott, Bent R and Zagkla, Styliani and Othmer, Till and Syunyaeva, Zulfiya and Graeber, Simon Y and Yoosefi, Mehrak and Thee, Stephanie and Steinke, Eva and Röhmel, Jobst and Mall, Marcus A and Stahl, Mirjam},
  title = {Elexacaftor/tezacaftor/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2024.03.003}
}
Kostenlos starten →